Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Drug

Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis

Fineline Cube Jul 3, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...

Company Medical Device

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Fineline Cube Jul 3, 2023

China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...

Company Deals

Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence

Fineline Cube Jul 3, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Deals

Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1

Fineline Cube Jul 3, 2023

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...

Company Drug

ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study

Fineline Cube Jul 3, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...

Company Drug

Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment

Fineline Cube Jul 3, 2023

The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...

Company Drug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...

Company Deals

Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development

Fineline Cube Jun 30, 2023

Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...

Company Drug

Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 30, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update

Fineline Cube Jun 30, 2023

The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...

Company Drug

Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection

Fineline Cube Jun 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC

Fineline Cube Jun 30, 2023

China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...

Company Drug

Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review

Fineline Cube Jun 30, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain

Fineline Cube Jun 30, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...

Medical Device

MicroPort MedBot’s Dragonfly Eye 3D Endoscopy Earns CE Mark for Intraperitoneal Procedures

Fineline Cube Jun 30, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its in-house developed Dragonfly...

Company Deals

Merck KGaA Expands High-Purity Reagents Production in Nantong, China with EUR 70 Million Investment

Fineline Cube Jun 30, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced plans to expand production capacity for highly-purified reagents...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model

Fineline Cube Jun 29, 2023

Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment

Fineline Cube Jun 29, 2023

China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...

Company Drug

Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis

Fineline Cube Jun 29, 2023

The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...

Posts pagination

1 … 445 446 447 … 603

Recent updates

  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.